Invech Holdings changes control: new CEO appointed, Rhonda Keaveney resigns; controlling stake sold for $350K

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

On May 7, 2026, as contemplated by the Business Combination Agreement and as described in the section titled “ The BCA Proposal ” beginning on pa ge 180 of the Proxy Statement/Prospectus, the Company, Enhanced and Merger Sub consummated the business combination contemplated by the Business Combination Agreement, whereby: • Merger Sub merged with and into Enhanced (the “First Merger”), with Enhanced surviving the merger as a wholly owned subsidiary of the Company;

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

On May 5, 2026 (the “Closing Date”), Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso” or the “Company”), consummated the previously announced business combination transaction (the “Business Combination”) contemplated by that certain Contribution and Exchange Agreement

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

On February 13, 2026, we entered into the Purchase Agreement with David Lazar, the First Closing Shares were issued on February 17, 2026, and the Second Closing Shares were issued on April 22, 2026. As a result of the transactions set out in the Purchase Agreement, Mr. Lazar became the holder of over 95% of the voting rights of our issued and outstanding shares, on a fully-diluted basis, and became the controlling shareholder.

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

On the Distribution Date, AnaptysBio completed the Spin-Off.

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

On April 8, 2026 (the “Closing Date”), Suncrete, Inc. (the “Company”) consummated its previously announced business combination (the “Closing”) pursuant to that certain Business Combination Agreement, dated October 9, 2025 (the “Business Combination Agreement”), by and among the Company, Haymaker Acquisition Corp. 4, a Cayman Islands exempted company (“Haymaker” or “SPAC”), Haymaker Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Merger Sub I”), Haymaker Merger Sub II, LLC, a Delaware limited liability company and direct wholly owned subsidiary of the Company (“Merger Sub II”), and Concrete Partners Holding, LLC, a Delaware limited liability company (“Suncrete”)

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

This Current Report on Form 8-K is being filed in connection with the completion of the spin-off of New Enviri contemplated by the Separation Agreement.

This filing

Agreement, SCC sold its control block of stock, 300,000 shares of Convertible Series A Preferred Stock and 90,000,000 shares of Restricted Common Stock for the purchase price of $350,000. The Agreement was fully executed on February 17, 2026. (See Exhibit 10.2) On February 12, 2026, the registrant’s majority shareholder, SCC entered into a Cancellation of Debt

Comparable filing

excluded shares pursuant to the terms of the Merger Agreement, was cancelled and extinguished and automatically converted into the right to receive an amount in cash equal to $5.80 per share of Class A Common Stock, without interest thereon (the “ Class A Per Share Price ”), (ii) each share of the Company’s Class B common stock, par value $0.00001 per share